A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 139,040 shares of VNDA stock, worth $785,576. This represents 0.0% of its overall portfolio holdings.

Number of Shares
139,040
Previous 36,412 281.85%
Holding current value
$785,576
Previous $153,000 273.2%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$3.47 - $4.61 $356,119 - $473,115
102,628 Added 281.85%
139,040 $571,000
Q4 2023

Feb 14, 2024

BUY
$3.38 - $4.58 $123,072 - $166,766
36,412 New
36,412 $153,000
Q4 2022

Feb 14, 2023

BUY
$6.87 - $10.96 $73,783 - $117,710
10,740 New
10,740 $79,000
Q2 2022

Aug 15, 2022

SELL
$9.31 - $11.84 $300,173 - $381,745
-32,242 Reduced 32.78%
66,114 $721,000
Q1 2022

May 16, 2022

BUY
$10.84 - $16.55 $334,370 - $510,501
30,846 Added 45.69%
98,356 $1.11 Million
Q4 2021

Feb 14, 2022

BUY
$15.69 - $21.14 $779,165 - $1.05 Million
49,660 Added 278.21%
67,510 $1.06 Million
Q3 2021

Nov 15, 2021

SELL
$15.35 - $21.27 $269,699 - $373,713
-17,570 Reduced 49.6%
17,850 $306,000
Q2 2021

Aug 16, 2021

SELL
$15.71 - $21.51 $311,576 - $426,607
-19,833 Reduced 35.89%
35,420 $762,000
Q1 2021

May 17, 2021

BUY
$13.42 - $20.28 $462,963 - $699,619
34,498 Added 166.22%
55,253 $830,000
Q4 2020

Feb 16, 2021

SELL
$9.77 - $13.81 $117,474 - $166,051
-12,024 Reduced 36.68%
20,755 $273,000
Q3 2020

Nov 16, 2020

BUY
$9.32 - $12.02 $63,189 - $81,495
6,780 Added 26.08%
32,779 $317,000
Q2 2020

Aug 14, 2020

SELL
$9.66 - $12.02 $807,682 - $1.01 Million
-83,611 Reduced 76.28%
25,999 $297,000
Q1 2020

May 15, 2020

BUY
$7.5 - $16.8 $156,090 - $349,641
20,812 Added 23.44%
109,610 $1.14 Million
Q4 2019

Feb 14, 2020

SELL
$12.38 - $17.47 $552,383 - $779,493
-44,619 Reduced 33.44%
88,798 $1.46 Million
Q3 2019

Nov 14, 2019

BUY
$12.27 - $15.79 $5,840 - $7,516
476 Added 0.36%
133,417 $1.77 Million
Q2 2019

Aug 14, 2019

BUY
$13.37 - $18.85 $492,831 - $694,829
36,861 Added 38.36%
132,941 $1.87 Million
Q1 2019

May 15, 2019

BUY
$17.59 - $31.05 $656,951 - $1.16 Million
37,348 Added 63.59%
96,080 $1.77 Million
Q4 2018

Feb 14, 2019

BUY
$18.97 - $31.47 $637,486 - $1.06 Million
33,605 Added 133.74%
58,732 $1.54 Million
Q3 2018

Nov 14, 2018

SELL
$18.25 - $23.0 $1.2 Million - $1.51 Million
-65,564 Reduced 72.29%
25,127 $577,000
Q2 2018

Aug 14, 2018

BUY
$13.95 - $19.15 $283,254 - $388,840
20,305 Added 28.85%
90,691 $1.73 Million
Q1 2018

May 15, 2018

BUY
$14.05 - $20.2 $719,556 - $1.03 Million
51,214 Added 267.13%
70,386 $1.19 Million
Q4 2017

Feb 14, 2018

BUY
$12.85 - $18.1 $58,878 - $82,934
4,582 Added 31.41%
19,172 $291,000
Q3 2017

Nov 14, 2017

BUY
$15.4 - $18.85 $224,686 - $275,021
14,590
14,590 $261,000

Others Institutions Holding VNDA

About Vanda Pharmaceuticals Inc.


  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $320M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.